Tibolone, sold under the brand name Livial among others, is a medication which is used in menopausal hormone therapy and in the treatment of postmenopausal osteoporosis and endometriosis. The medication is available alone and is not formulated or used in combination with other medications. It is taken by mouth. Side effects of tibolone include acne and increased hair growth among others. Tibolone is a synthetic steroid with weak estrogenic, progestogenic, and androgenic activity, and hence is an agonist of the estrogen, progesterone, and androgen receptors. It is a prodrug of several metabolites. The estrogenic effects of tibolone may show tissue selectivity in their distribution. Tibolone was developed in the 1960s and was introduced for medical use in 1988. It is marketed widely throughout the world. The medication is not available in the United States.
Medical uses Tibolone is used in the treatment of menopausal symptoms like hot flashes and vaginal atrophy, postmenopausal osteoporosis, and endometriosis. It has similar or greater effectiveness compared to older menopausal hormone therapy medications, but shares a similar side effect profile. It has also been investigated as a possible treatment for female sexual dysfunction. Tibolone reduces hot flashes, prevents bone loss, improves vaginal atrophy and urogenital symptoms (e.g., vaginal dryness, dyspareunia), and has positive effects on mood and sexual function. The medication may have greater benefits on libido than standard menopausal hormone therapy, which may be related to its androgenic effects. It is associated with low rates of vaginal bleeding and breast pain. A 2015 network meta-analysis of randomized controlled trials found that tibolone was associated with a significantly decreased risk of breast cancer (RRTooltip relative risk = 0.317). The decrease in risk was greater than that observed with most of the aromatase inhibitors and selective estrogen receptor modulators that were included in the analysis. However, paradoxically, other research has found evidence supporting an increased risk of breast cancer with tibolone.
Available forms Tibolone is available in the form of 2.5 mg oral tablets. It is typically used once daily at a dosage of 1.25 or 2.5 mg.
Side effects A report in September 2009 from Health and Human Services' Agency for Healthcare Research and Quality suggests that tamoxifen, raloxifene, and tibolone used to reduce the risk of breast cancer significantly reduce the occurrence of invasive breast cancer in midlife and older women, but also increase the risk of adverse effects. Tibolone can infrequently produce androgenic side effects such as acne and increased facial hair growth. Such side effects have been found to occur in 3 to 6% of treated women. A 2016 Cochrane review has been published on the short-term and long-term effects of tibolone, including adverse effects. Possible adverse effects of tibolone include unscheduled vaginal bleeding (ORTooltip Odds ratio = 2.79; incidence 13–26% more than placebo), an increased risk of breast cancer in women with a history of breast cancer (ORTooltip Odds ratio = 1.5) although apparently not without a history of breast cancer (ORTooltip Odds ratio = 0.52), an increased risk of cerebrovascular events (strokes) (ORTooltip Odds ratio = 1.74) and cardiovascular events (ORTooltip Odds ratio = 1.38), and an increased risk of endometrial cancer (ORTooltip Odds ratio = 2.04). However, most of these figures are based on very low-quality evidence. Tibolone has been associated with increased risk of endometrial cancer in most studies.
Pharmacology
Pharmacodynamics
Tibolone possesses a complex pharmacology and has weak estrogenic, progestogenic, and androgenic activity. Tibolone, 3α-hydroxytibolone, and 3β-hydroxytibolone act as agonists of the estrogen receptors. Tibolone and its metabolite δ4-tibolone act as agonists of the progesterone and androgen receptors, while 3α-hydroxytibolone and 3β-hydroxytibolone, conversely, act as antagonists of these receptors. Relative to other progestins, tibolone, including its metabolites, has been described as possessing moderate functional antiestrogenic activity (that is, progestogenic activity), moderate estrogenic activity, high androgenic activity, and no clinically significant glucocorticoid, antiglucocorticoid, mineralocorticoid, or antimineralocorticoid activity. The ovulation-inhibiting dosage of tibolone is 2.5 mg/day.
… excerpt ends here. Continue reading the full article.




![Tibolone: Tibolone metabolism.[8]](https://upload.wikimedia.org/wikipedia/commons/thumb/3/3d/Tibolone_metabolism.png/500px-Tibolone_metabolism.png?utm_source=en.wikipedia.org&utm_campaign=parser&utm_content=thumbnail)

